Dyslipidemia in Type 2 Diabetes (0767-034)

Merck Sharp & Dohme (MSD)

Status and phase

Terminated

Phase 3

Conditions

Diabetes Mellitus, Type II

Dyslipidemia

Treatments

Drug: MK0767

Study type

Interventional

Funder types

Industry

Identifiers

NCT00547274

0767-034

MK-0767-034

2007_635

Details and patient eligibility

About

The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Enrollment

111 patients

Sex

All

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Men and non-pregnant females
Age greater than or equal to 21 years
Stop current diabetes therapy (if applicable)
Stop current statin therapy (if applicable)

Exclusion criteria

History of type 1 diabetes mellitus or ketoacidosis who are currently being treated with insulin
Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within the last four weeks
Patients requiring treatment with corticosteroids for more than 14 consecutive days
Patients taking warfarin or warfarin-like anti-coagulants
Patients undergoing surgery within 30 days of Visit 1
Patients with Hepatitis B, Hepatitis C, active liver or gallbladder disease
Patients with history of pancreatitis or uncontrolled high blood pressure